<DOC>
	<DOC>NCT02109445</DOC>
	<brief_summary>This study consists of a Phase 1b portion aimed to determine the maximum tolerated dose and the safety profile of PF-03084014 in combination with gemcitabine and nab-paclitaxel followed by a Phase 2 portion to evaluate the efficacy of the triple combination in terms of overall survival in patients with metastatic pancreatic ductal adenocarcinoma not previously treated with anticancer therapies.</brief_summary>
	<brief_title>Study Of PF-03084014 In Combination With Gemcitabine And Nab-Paclitaxel In Patients With Metastatic Pancreatic Adenocarcinoma Not Previously Treated With Anticancer Therapies</brief_title>
	<detailed_description />
	<mesh_term>Adenocarcinoma</mesh_term>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<criteria>Histologically or cytologically diagnosis of metastatic ductal adenocarcinoma of the pancreas. No prior radiotherapy, surgery chemotherapy or investigational therapy for metastatic disease. Prior adjuvant therapy with 5FU or gemcitabine (Â± gemcitabine post radiation) administered as radiosensitizer allowed, provided at least 6 months have elapsed between the last dose and study registration Tumor tissue available (Archival 6 months old or de novo biopsy) Measurable disease as per RECIST 1.1 Performance Status (ECOG) 0 or 1 Symptomatic brain metastases requiring steroids Prior therapy with gamma secretase inhibitors or other Notch pathway inhibitor Major surgery within 4 weeks of registration in the current study Known hypersensitivity to gemcitabine or nabpaclitaxel or any of the excipients Current or anticipated need for food or drugs that are strong/moderate CYP3A4 inhibitors or inducers Diagnosis of any second malignancy within 3 years prior to registration</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2015</verification_date>
</DOC>